Alpha Tau Medical reported encouraging Phase 3 clinical trial results for Alpha DaRT, a localized alpha radiation therapy for solid tumors. The treatment elicits both local tumor control and systemic immune responses against untreated tumors, as evidenced by patient case studies and animal models. When combined with pembrolizumab immunotherapy, Alpha DaRT increased complete response rates from 5% to 37.5% and overall response rates to 75%, indicating synergistic potential. The technology, designated a breakthrough device by the FDA, induces DNA double-strand breaks causing tumor regression while preserving healthy tissue.